These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 9735103)

  • 21. Raman crystallographic studies of the intermediates formed by Ser130Gly SHV, a beta-lactamase that confers resistance to clinical inhibitors.
    Helfand MS; Taracila MA; Totir MA; Bonomo RA; Buynak JD; van den Akker F; Carey PR
    Biochemistry; 2007 Jul; 46(29):8689-99. PubMed ID: 17595114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of the inhibitor-resistant M69V substitution on the structures and populations of trans-enamine beta-lactamase intermediates.
    Totir MA; Padayatti PS; Helfand MS; Carey MP; Bonomo RA; Carey PR; van den Akker F
    Biochemistry; 2006 Oct; 45(39):11895-904. PubMed ID: 17002290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clavulanic acid inactivation of SHV-1 and the inhibitor-resistant S130G SHV-1 beta-lactamase. Insights into the mechanism of inhibition.
    Sulton D; Pagan-Rodriguez D; Zhou X; Liu Y; Hujer AM; Bethel CR; Helfand MS; Thomson JM; Anderson VE; Buynak JD; Ng LM; Bonomo RA
    J Biol Chem; 2005 Oct; 280(42):35528-36. PubMed ID: 15987690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-function analysis of alpha-helix H4 using PSE-4 as a model enzyme representative of class A beta-lactamases.
    Savoie A; Sanschagrin F; Palzkill T; Voyer N; Levesque RC
    Protein Eng; 2000 Apr; 13(4):267-74. PubMed ID: 10810158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CTX-M-190, a Novel β-Lactamase Resistant to Tazobactam and Sulbactam, Identified in an Escherichia coli Clinical Isolate.
    Shen Z; Ding B; Bi Y; Wu S; Xu S; Xu X; Guo Q; Wang M
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli to 12 beta-lactam agents and combinations with beta-lactamase inhibitors.
    Tajada P; Gomez-Graces JL; Alós JI; Balas D; Cogollos R
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1924-5. PubMed ID: 8843305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical inhibitor-resistant mutants of the beta-lactamase TEM-1 at amino-acid position 69. Kinetic analysis and molecular modelling.
    Chaibi EB; Péduzzi J; Farzaneh S; Barthélémy M; Sirot D; Labia R
    Biochim Biophys Acta; 1998 Jan; 1382(1):38-46. PubMed ID: 9507060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ceftazidime and aztreonam resistance in Providencia stuartii: characterization of a natural TEM-derived extended-spectrum beta-lactamase, TEM-60.
    Franceschini N; Perilli M; Segatore B; Setacci D; Amicosante G; Mazzariol A; Cornaglia G
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1459-62. PubMed ID: 9624494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Construction and characterization of mutants of the TEM-1 beta-lactamase containing amino acid substitutions associated with both extended-spectrum resistance and resistance to beta-lactamase inhibitors.
    Stapleton PD; Shannon KP; French GL
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1881-7. PubMed ID: 10428907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selection and characterization of beta-lactam-beta-lactamase inactivator-resistant mutants following PCR mutagenesis of the TEM-1 beta-lactamase gene.
    Vakulenko SB; Geryk B; Kotra LP; Mobashery S; Lerner SA
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1542-8. PubMed ID: 9660980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selection of variants of the TEM-1 beta-lactamase, encoded by a plasmid of clinical origin, with increased resistance to beta-lactamase inhibitors.
    Thomson CJ; Amyes SG
    J Antimicrob Chemother; 1993 May; 31(5):655-64. PubMed ID: 8392995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A kinetic study of NMC-A beta-lactamase, an Ambler class A carbapenemase also hydrolyzing cephamycins.
    Mariotte-Boyer S; Nicolas-Chanoine MH; Labia R
    FEMS Microbiol Lett; 1996 Sep; 143(1):29-33. PubMed ID: 8807798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tazobactam inactivation of SHV-1 and the inhibitor-resistant Ser130 -->Gly SHV-1 beta-lactamase: insights into the mechanism of inhibition.
    Pagan-Rodriguez D; Zhou X; Simmons R; Bethel CR; Hujer AM; Helfand MS; Jin Z; Guo B; Anderson VE; Ng LM; Bonomo RA
    J Biol Chem; 2004 May; 279(19):19494-501. PubMed ID: 14757767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutations altering substrate specificity in OHIO-1, and SHV-1 family beta-lactamase.
    Shlaes DM; Currie-McCumber C
    Biochem J; 1992 Jun; 284 ( Pt 2)(Pt 2):411-5. PubMed ID: 1599426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cloning and sequencing of the gene encoding Toho-2, a class A beta-lactamase preferentially inhibited by tazobactam.
    Ma L; Ishii Y; Ishiguro M; Matsuzawa H; Yamaguchi K
    Antimicrob Agents Chemother; 1998 May; 42(5):1181-6. PubMed ID: 9593147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Properties of mutant SHV-5 beta-lactamases constructed by substitution of isoleucine or valine for methionine at position 69.
    Giakkoupi P; Miriagou V; Gazouli M; Tzelepi E; Legakis NJ; Tzouvelekis LS
    Antimicrob Agents Chemother; 1998 May; 42(5):1281-3. PubMed ID: 9593168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of the inhibitor-resistant SHV β-lactamase SHV-107 in a clinical Klebsiella pneumoniae strain coproducing GES-7 enzyme.
    Manageiro V; Ferreira E; Cougnoux A; Albuquerque L; Caniça M; Bonnet R
    Antimicrob Agents Chemother; 2012 Feb; 56(2):1042-6. PubMed ID: 22083476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Substitutions at position 105 in SHV family β-lactamases decrease catalytic efficiency and cause inhibitor resistance.
    Li M; Conklin BC; Taracila MA; Hutton RA; Skalweit MJ
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5678-86. PubMed ID: 22908166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of a second-shell residue in modifying substrate and inhibitor interactions in the SHV beta-lactamase: a study of ambler position Asn276.
    Drawz SM; Bethel CR; Hujer KM; Hurless KN; Distler AM; Caselli E; Prati F; Bonomo RA
    Biochemistry; 2009 Jun; 48(21):4557-66. PubMed ID: 19351161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.